# BBNX (Beta Bionics, Inc.) - SEC EDGAR Financial Statements

> Beta Bionics, Inc. reported $127.3M in revenue and a net loss of $83.12M for the trailing twelve months ended September 30, 2026 (up 30.3% year over year), with a 58.6% gross margin and a -72.7% operating margin.

- Canonical: https://convexityos.com/fundamentals/BBNX
- Markdown: https://convexityos.com/fundamentals/BBNX.md
- SEC CIK: 0001674632
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:33 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001674632&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | TTM | $127.3M | +30.3% YoY |
| Operating Income | TTM | -$92.58M | -72.7% margin |
| Net Income | TTM | -$83.12M | -65.3% net margin |
| Diluted EPS | TTM | -$1.79 | Split-adjusted |
| Free Cash Flow | TTM | -$65.96M | -51.8% FCF margin |
| Cash & ST Investments | Sep 30, 2026 | $240.2M | Total debt: $6.10M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Revenue** | $100.3M | $65.12M | $11.99M |
| Cost of Revenue | $44.71M | $29.24M | $5.69M |
| **Gross Profit** | $55.54M | $35.89M | $6.31M |
| Research & Development | $34.79M | $26.18M | $17.94M |
| Selling, General & Admin | $92.43M | $54.95M | $24.21M |
| Total Operating Expenses | $127.2M | $81.14M | $42.16M |
| **Operating Income** | -$71.68M | -$45.25M | -$35.85M |
| **EBITDA** | -$70.11M | -$44.10M | -$34.62M |
| Interest Income | $10.93M | $3.91M | $1.78M |
| Income Tax Expense | $0 | $0 | -- |
| **Net Income** | -$73.20M | -$54.76M | -$44.10M |
| Basic EPS | -$1.81 | -$8.60 | -$16.37 |
| **Diluted EPS** | -$1.81 | -$8.60 | -$16.37 |
| Basic Shares Outstanding | 40.5M | 6.4M | 2.7M |
| Diluted Shares Outstanding | 40.5M | 6.4M | 2.7M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $35.51M | $32.01M | $27.63M | $32.12M | $27.25M | $23.24M | $17.64M | $20.44M |
| Cost of Revenue | $15.17M | $13.11M | $11.19M | $13.18M | $12.13M | $10.73M | $8.67M | $8.75M |
| **Gross Profit** | $20.33M | $18.90M | $16.44M | $18.94M | $15.12M | $12.50M | $8.97M | $11.69M |
| Research & Development | $11.97M | $10.24M | $10.36M | $10.13M | $8.20M | $8.87M | $7.59M | $9.21M |
| Selling, General & Admin | $34.97M | $34.24M | $30.35M | $24.94M | $23.97M | $23.50M | $20.02M | $15.51M |
| Total Operating Expenses | $46.94M | $44.48M | $40.71M | $35.07M | $32.16M | $32.38M | $27.61M | $24.73M |
| **Operating Income** | -$26.61M | -$25.58M | -$24.27M | -$16.12M | -$17.04M | -$19.87M | -$18.64M | -$13.04M |
| **EBITDA** | -$25.72M | -$24.87M | -$23.69M | -$15.59M | -$16.66M | -$19.52M | -$18.34M | -$12.80M |
| Interest Income | $2.26M | $2.18M | $2.38M | $2.66M | $2.83M | $3.00M | $2.44M | $951K |
| **Net Income** | -$24.35M | -$23.40M | -$21.89M | -$13.47M | -$14.21M | -$16.87M | -$28.66M | -$18.11M |
| Basic EPS | -$0.52 | -$0.53 | -$0.49 | -- | -$0.33 | -$0.39 | -$0.93 | -- |
| **Diluted EPS** | -$0.52 | -$0.53 | -$0.49 | -- | -$0.33 | -$0.39 | -$0.93 | -- |
| Basic Shares Outstanding | 46.5M | 44.5M | 44.4M | -- | 43.6M | 43.4M | 30.7M | -- |
| Diluted Shares Outstanding | 46.5M | 44.5M | 44.4M | -- | 43.6M | 43.4M | 30.7M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $31.58M | $30.43M | $26.57M |
| Short-Term Investments | $187.5M | $73.14M | $70.18M |
| **Cash & Short-Term Investments** | $219.1M | $103.6M | $96.75M |
| Accounts Receivable, Net | $17.12M | $12.00M | $4.45M |
| Inventory | $21.72M | $13.32M | $1.25M |
| Other Current Assets | -- | $817K | $275K |
| **Total Current Assets** | $267.9M | $132.9M | $103.6M |
| Property, Plant & Equipment, Net | $8.60M | $4.78M | $2.48M |
| Long-Term Investments | $45.43M | -- | -- |
| Other Non-Current Assets | $180K | $150K | $121K |
| **Total Non-Current Assets** | $60.84M | $16.72M | $6.42M |
| **Total Assets** | $328.7M | $149.6M | $110.0M |
| Accounts Payable | $5.00M | $2.85M | $1.17M |
| Deferred Revenue (Current) | $1.56M | $939K | $87K |
| **Total Current Liabilities** | $30.92M | $21.15M | $10.61M |
| Deferred Revenue (Non-Current) | $3.30M | $1.86M | $255K |
| Other Non-Current Liabilities | $1.55M | -- | -- |
| **Total Non-Current Liabilities** | $10.21M | $52.48M | $40.83M |
| **Total Liabilities** | $41.13M | $73.63M | $51.43M |
| **Total Debt (incl. Leases)** | $7.30M | $7.25M | $4.22M |
| Common Stock | $4.0K | $1.0K | -- |
| Retained Earnings | -$369.9M | -$296.7M | -$229.7M |
| Accumulated Other Comp. Income | $403K | $65K | $137K |
| **Total Stockholders' Equity** | $287.6M | -$245.4M | -$203.1M |
| Total Equity | $287.6M | -$245.4M | -$203.1M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $81.55M | $44.32M | $30.21M | $31.58M | $38.48M | $35.08M | $42.45M | $30.43M |
| Short-Term Investments | $158.7M | $136.2M | $169.3M | $187.5M | $190.2M | $214.6M | $189.0M | $73.14M |
| **Cash & Short-Term Investments** | $240.2M | $180.5M | $199.5M | $219.1M | $228.7M | $249.7M | $231.5M | $103.6M |
| Accounts Receivable, Net | $20.67M | $18.05M | $15.75M | $17.12M | $11.54M | $11.39M | $9.06M | $12.00M |
| Inventory | $22.97M | $23.92M | $23.73M | $21.72M | $20.37M | $17.32M | $15.73M | $13.32M |
| Other Current Assets | -- | -- | -- | -- | $265K | $260K | $260K | $817K |
| **Total Current Assets** | $292.9M | $231.0M | $248.0M | $267.9M | $270.0M | $286.1M | $261.9M | $132.9M |
| Property, Plant & Equipment, Net | $11.76M | $10.75M | $10.16M | $8.60M | $7.38M | $6.46M | $5.51M | $4.78M |
| Long-Term Investments | $133.4M | $44.65M | $39.87M | $45.43M | $45.33M | $31.15M | $64.00M | -- |
| Other Non-Current Assets | $212K | $141K | $181K | $180K | $183K | $144K | $146K | $150K |
| **Total Non-Current Assets** | $150.8M | $61.35M | $56.43M | $60.84M | $60.02M | $43.90M | $76.11M | $16.72M |
| **Total Assets** | $443.8M | $292.4M | $304.4M | $328.7M | $330.0M | $330.0M | $338.0M | $149.6M |
| Accounts Payable | $4.68M | $5.35M | $2.32M | $5.00M | $4.46M | $3.42M | $3.45M | $2.85M |
| Deferred Revenue (Current) | $2.05M | $1.88M | $1.71M | $1.56M | $1.34M | $1.14M | $949K | $939K |
| **Total Current Liabilities** | $32.84M | $26.02M | $23.19M | $30.92M | $25.39M | $19.49M | $16.49M | $21.15M |
| Deferred Revenue (Non-Current) | $3.48M | $3.45M | $3.35M | $3.30M | $2.99M | $2.67M | $2.33M | $1.86M |
| Other Non-Current Liabilities | $1.41M | $1.63M | $1.56M | $1.55M | $1.21M | $1.01M | -- | -- |
| **Total Non-Current Liabilities** | $9.54M | $10.00M | $9.98M | $10.21M | $9.90M | $8.85M | $7.78M | $52.48M |
| **Total Liabilities** | $42.38M | $36.02M | $33.17M | $41.13M | $35.29M | $28.34M | $24.27M | $73.63M |
| **Total Debt (incl. Leases)** | $6.10M | $6.51M | $6.91M | $7.30M | $7.69M | $6.69M | $6.97M | $7.25M |
| Common Stock | $5.0K | $5.0K | $5.0K | $4.0K | $4.0K | $4.0K | $4.0K | $1.0K |
| Retained Earnings | -$439.6M | -$415.2M | -$391.8M | -$369.9M | -$356.5M | -$342.3M | -$325.4M | -$296.7M |
| Accumulated Other Comp. Income | -$877K | -$390K | -$96K | $403K | $354K | $149K | $240K | $65K |
| **Total Stockholders' Equity** | $401.4M | $256.4M | $271.2M | $287.6M | $294.8M | $301.6M | $313.8M | -$245.4M |
| Total Equity | $401.4M | $256.4M | $271.2M | $287.6M | $294.8M | $301.6M | $313.8M | -$245.4M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$73.20M | -$54.76M | -$44.10M |
| Depreciation & Amortization | $1.57M | $1.15M | $1.23M |
| Stock-Based Compensation | $16.38M | $6.38M | $5.66M |
| Change in Receivables | -$5.16M | -$7.62M | -$4.49M |
| Change in Inventory | -$9.88M | -$11.44M | -$1.19M |
| Change in Payables | $2.10M | $1.51M | $716K |
| **Operating Cash Flow** | -$50.92M | -$48.27M | -$32.45M |
| Capital Expenditure | -$5.30M | -$3.40M | -$402K |
| **Free Cash Flow** | -$56.22M | -$51.67M | -$32.85M |
| **Investing Cash Flow** | -$162.8M | -$3.48M | -$69.69M |
| Common Stock Issued | $194.5M | -- | -- |
| **Financing Cash Flow** | $214.9M | $55.62M | $101.0M |
| **Net Change in Cash** | $1.14M | $3.87M | -$1.11M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$24.35M | -$23.40M | -$21.89M | -$13.47M | -$14.21M | -$16.87M | -$28.66M | -$18.11M |
| Depreciation & Amortization | $892K | $709K | $585K | $538K | $385K | $347K | $303K | $232K |
| Stock-Based Compensation | $6.71M | $7.02M | $5.41M | $4.30M | $4.48M | $4.80M | $2.80M | $1.55M |
| Change in Receivables | -$2.65M | -$2.32M | $1.37M | -$5.59M | -$168K | -$2.33M | $2.94M | -$4.56M |
| Change in Inventory | $1.33M | -$214K | -$1.80M | -$2.20M | -$3.33M | -$1.73M | -$2.62M | -$1.21M |
| Change in Payables | -$352K | $2.86M | -$3.33M | $527K | $1.10M | $568K | -$97K | -$61K |
| **Operating Cash Flow** | -$12.29M | -$14.62M | -$23.83M | -$8.63M | -$8.73M | -$13.59M | -$19.98M | -$14.28M |
| Capital Expenditure | -$2.27M | -$1.04M | -$1.38M | -$1.90M | -$1.28M | -$1.78M | -$333K | -$561K |
| **Free Cash Flow** | -$14.56M | -$15.66M | -$25.21M | -$10.53M | -$10.01M | -$15.37M | -$20.31M | -$14.84M |
| **Investing Cash Flow** | -$114.1M | $26.93M | $21.84M | $658K | $9.49M | $6.17M | -$179.1M | -$29.66M |
| Common Stock Issued | -- | -- | -- | -$904K | $0 | $0 | $195.4M | -- |
| **Financing Cash Flow** | $163.6M | $1.80M | $623K | $1.06M | $2.65M | $42K | $211.1M | $56.89M |
| **Net Change in Cash** | $37.23M | $14.11M | -$1.37M | -$6.91M | $3.41M | -$7.38M | $12.02M | $12.95M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| **Gross Margin** | 55.4% | 55.1% | 52.6% |
| **Operating Margin** | -71.5% | -69.5% | -298.9% |
| **Net Profit Margin** | -73.0% | -84.1% | -367.6% |
| Return on Equity (ROE) | -25.5% | -- | -- |
| Return on Assets (ROA) | -22.3% | -36.6% | -40.1% |
| Current Ratio | 8.66x | 6.29x | 9.77x |
| Quick Ratio | 7.96x | 5.66x | 9.65x |
| Debt to Equity | 0.03x | -- | -- |
| **Revenue Growth (YoY)** | +53.9% | +442.9% | -- |
| Gross Profit Growth (YoY) | +54.8% | +468.9% | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Gross Margin** | 58.6% | 58.3% | 57.2% | 55.4% | 54.5% | 53.9% | 53.9% | 55.1% |
| **Operating Margin** | -72.7% | -69.8% | -70.1% | -71.5% | -77.4% | -80.1% | -78.0% | -69.5% |
| **Net Profit Margin** | -65.3% | -61.3% | -60.3% | -73.0% | -87.9% | -94.0% | -101.6% | -84.1% |
| Return on Equity (ROE) | -20.7% | -28.5% | -24.5% | -25.5% | -26.4% | -24.3% | -22.6% | -- |
| Return on Assets (ROA) | -18.7% | -25.0% | -21.8% | -22.3% | -23.6% | -22.2% | -21.0% | -36.6% |
| Current Ratio | 8.92x | 8.88x | 10.69x | 8.66x | 10.64x | 14.68x | 15.88x | 6.29x |
| Quick Ratio | 8.22x | 7.96x | 9.67x | 7.96x | 9.83x | 13.79x | 14.93x | 5.66x |
| Debt to Equity | 0.02x | 0.03x | 0.03x | 0.03x | 0.03x | 0.02x | 0.02x | -- |
| **Revenue Growth (YoY)** | +30.3% | +37.8% | +56.6% | +57.1% | +63.1% | +54.4% | +36.4% | -- |
| Gross Profit Growth (YoY) | +34.5% | +51.2% | +83.2% | +62.1% | +69.6% | +54.7% | +24.6% | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
